An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 2 to 5 Years)
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Granisetron (Primary) ; Granisetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Pharmacokinetics
- Sponsors Kyowa Kirin Pharmaceutical Development
- 01 Mar 2017 Planned End Date changed from 1 Oct 2015 to 1 Dec 2018.
- 01 Mar 2017 Planned primary completion date changed from 1 Oct 2015 to 1 Dec 2018.
- 01 Mar 2017 Planned initiation date changed from 1 Jul 2014 to 1 Jul 2018.